AIM ImmunoTech (NYSEMKT:AIM) has filed
a provisional patent application for the use of its experimental drug
Ampligen as a potential early-onset therapy for the treatment of
COVID-19 induced chronic fatigue, which shows similarities to Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
https://seekingalpha.com/news/3582287-aim-immunotech-files-provisional-patent-for-use-of-ampligen-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.